Ryo Ariyasu

763 total citations
51 papers, 444 citations indexed

About

Ryo Ariyasu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ryo Ariyasu has authored 51 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Ryo Ariyasu's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (18 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Ryo Ariyasu is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (18 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Ryo Ariyasu collaborates with scholars based in Japan, United Kingdom and Spain. Ryo Ariyasu's co-authors include Noriko Yanagitani, Makoto Nishio, Satoru Kitazono, Ken Uchibori, Shingo Nishikawa, Junji Koyama, Atsushi Horiike, Takahiro Yoshizawa, Hironori Ninomiya and Takehiro Tozuka and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Investigative Dermatology.

In The Last Decade

Ryo Ariyasu

47 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryo Ariyasu Japan	13	273	266	104	81	50	51	444
Seong Woo Hong South Korea	11	234 0.9×	126 0.5×	114 1.1×	87 1.1×	65 1.3×	28	458
Diego Kauffmann‐Guerrero Germany	11	279 1.0×	264 1.0×	67 0.6×	91 1.1×	59 1.2×	59	459
Pedro Rocha Spain	11	260 1.0×	173 0.7×	105 1.0×	70 0.9×	68 1.4×	33	444
Dian Ren China	12	136 0.5×	165 0.6×	76 0.7×	95 1.2×	55 1.1×	26	325
Shinsuke Shiotsu Japan	11	328 1.2×	276 1.0×	27 0.3×	53 0.7×	40 0.8×	41	459
Till Plönes Germany	12	180 0.7×	224 0.8×	53 0.5×	85 1.0×	44 0.9×	53	406
Alessandra Ferro Italy	11	183 0.7×	174 0.7×	76 0.7×	79 1.0×	24 0.5×	37	315
Atsuro Saijo Japan	11	187 0.7×	141 0.5×	50 0.5×	120 1.5×	33 0.7×	28	374
Chunxia Du China	7	280 1.0×	206 0.8×	47 0.5×	96 1.2×	50 1.0×	21	421
Veronica Placencio-Hickok United States	10	207 0.8×	107 0.4×	98 0.9×	161 2.0×	40 0.8×	30	419

Countries citing papers authored by Ryo Ariyasu

Since Specialization

Citations

This map shows the geographic impact of Ryo Ariyasu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryo Ariyasu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryo Ariyasu more than expected).

Fields of papers citing papers by Ryo Ariyasu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryo Ariyasu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryo Ariyasu. The network helps show where Ryo Ariyasu may publish in the future.

Co-authorship network of co-authors of Ryo Ariyasu

This figure shows the co-authorship network connecting the top 25 collaborators of Ryo Ariyasu. A scholar is included among the top collaborators of Ryo Ariyasu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryo Ariyasu. Ryo Ariyasu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bar, Jair, et al.. (2025). 2792TiP A phase Ib/II study of gocatamig (MK-6070; HPN328) and ifinatamab deruxtecan for relapsed/refractory extensive-stage small cell lung cancer (ES-SCLC). Annals of Oncology. 36. S1385–S1386.

Fujishima, Seitaro, Masahiro Ito, Ryo Ariyasu, et al.. (2025). Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens. Lung Cancer. 204. 108555–108555. 3 indexed citations

Uchibori, Ken, et al.. (2024). Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers. 16(21). 3712–3712. 1 indexed citations

Uchibori, Ken, Takahiro Akita, Ryo Ariyasu, et al.. (2024). Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion. Thoracic Cancer. 15(5). 402–409. 1 indexed citations

Akita, Takahiro, Ryo Ariyasu, Ken Uchibori, et al.. (2024). Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers. Thoracic Cancer. 15(10). 788–796. 2 indexed citations

Ariyasu, Ryo, Takahiro Akita, Ken Uchibori, et al.. (2023). Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 4(6). 100524–100524. 4 indexed citations

Low, Siew‐Kee, Hironori Ninomiya, Takahiro Akita, et al.. (2023). Clinical characteristics of patients with KRAS mutation detected by liquid biopsy. Thoracic Cancer. 14(33). 3317–3322. 2 indexed citations

Hasegawa, Tsukasa, Ryo Ariyasu, Hisashi Tanaka, et al.. (2023). Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02). Cancer Chemotherapy and Pharmacology. 92(1). 29–37. 6 indexed citations

Ariyasu, Ryo, Mitsutomi Ishiyama, Toshiaki Mochizuki, et al.. (2022). Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imaging. International Cancer Conference Journal. 12(2). 109–114. 2 indexed citations

10.

Yoshizawa, Takahiro, Ken Uchibori, Mitsugu Araki, et al.. (2021). Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. npj Precision Oncology. 5(1). 32–32. 16 indexed citations

11.

Ariyasu, Ryo, Ken Uchibori, Takaaki Sasaki, et al.. (2021). Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR. Cancer Science. 112(6). 2371–2380. 8 indexed citations

12.

Sakamoto, Hiroaki, Noriko Yanagitani, Takehiro Tozuka, et al.. (2021). Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib. Cancer Reports. 4(6). e1414–e1414. 2 indexed citations

13.

Uchibori, Ken, Takehiro Tozuka, Hiroaki Sakamoto, et al.. (2021). Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2. Thoracic Cancer. 12(6). 906–913. 4 indexed citations

14.

Ariyasu, Ryo, Ken Uchibori, Hironori Ninomiya, et al.. (2020). Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice. Thoracic Cancer. 12(4). 504–511. 15 indexed citations

15.

Ariyasu, Ryo, Noriko Yanagitani, Toshikazu Yamaguchi, et al.. (2020). Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. Cancer Chemotherapy and Pharmacology. 86(4). 517–525. 3 indexed citations

16.

Hasegawa, Tsukasa, Noriko Yanagitani, Fumiyoshi Ohyanagi, et al.. (2020). Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. International Journal of Clinical Oncology. 26(3). 507–514.

17.

Yoshizawa, Takahiro, Ryo Ariyasu, Junji Koyama, et al.. (2019). Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. Lung Cancer. 133. 4–9. 5 indexed citations

18.

Inozume, Takashi, Tomonori Yaguchi, Ryo Ariyasu, et al.. (2019). Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy. Journal of Investigative Dermatology. 139(7). 1490–1496. 14 indexed citations

19.

Inozume, Takashi, Tomonori Yaguchi, Ryo Ariyasu, et al.. (2019). 774 Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost MHC class I expression after anti-PD-1 therapy. Journal of Investigative Dermatology. 139(5). S134–S134.

20.

Nishikawa, Shingo, Rie Sakakibara, Ryo Ariyasu, et al.. (2018). EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer. Respiratory Medicine Case Reports. 24. 19–21. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact